TY - JOUR
T1 - A novel gene expression system strongly enhances the anticancer effects of a REIC/Dkk-3-encoding adenoviral vector
AU - Watanabe, Masami
AU - Sakaguchi, Masakiyo
AU - Kinoshita, Rie
AU - Kaku, Haruki
AU - Ariyoshi, Yuichi
AU - Ueki, Hideo
AU - Tanimoto, Ryuta
AU - Ebara, Shin
AU - Ochiai, Kazuhiko
AU - Futami, Junichiro
AU - Li, Shun Ai
AU - Huang, Peng
AU - Nasu, Yasutomo
AU - Huh, Nam Ho
AU - Kumon, Hiromi
PY - 2014/3
Y1 - 2014/3
N2 - Gene expression systems with various promoters, including the cytomegalovirus (CMV) promoter, have been developed to increase the gene expression in a variety of normal and cancer cells. In particular, in the clinical trials of cancer gene therapy, a more efficient and robust gene expression system is required to achieve sufficient therapeutic outcomes. By inserting the triple translational enhancer sequences of human telomerase reverse transcriptase (hTERT), Simian virus 40 (SV40) and CMV downstream of the sequence of the BGH polyA, we were able to develop a novel gene expression system that significantly enhances the expression of the genes of interest. We termed this novel gene expression cassette the super gene expression (SGE) system, and herein verify the utility of the SGE cassette for a replication-deficient adenoviral vector. We newly developed an adenoviral vector expressing the tumor suppressor, reduced expression in immortalized cells (REIC)/Dickkopf-3 (Dkk-3), based on the CMV promoter-driven SGE system (Ad-SGE-REIC) and compared the therapeutic utility of Ad-SGE-REIC with that of the conventional adenoviral vectors (Ad-CMV-REIC or Ad-CAG-REIC). The results demonstrated that the CMV promoter-SGE system allows for more potent gene expression, and that the Ad-SGE-REIC is superior to conventional adenoviral systems in terms of the REIC protein expression and therapeutic effects. Since the SGE cassette can be applied for the expression of various therapeutic genes using various vector systems, we believe that this novel system will become an innovative tool in the field of gene expression and gene therapy.
AB - Gene expression systems with various promoters, including the cytomegalovirus (CMV) promoter, have been developed to increase the gene expression in a variety of normal and cancer cells. In particular, in the clinical trials of cancer gene therapy, a more efficient and robust gene expression system is required to achieve sufficient therapeutic outcomes. By inserting the triple translational enhancer sequences of human telomerase reverse transcriptase (hTERT), Simian virus 40 (SV40) and CMV downstream of the sequence of the BGH polyA, we were able to develop a novel gene expression system that significantly enhances the expression of the genes of interest. We termed this novel gene expression cassette the super gene expression (SGE) system, and herein verify the utility of the SGE cassette for a replication-deficient adenoviral vector. We newly developed an adenoviral vector expressing the tumor suppressor, reduced expression in immortalized cells (REIC)/Dickkopf-3 (Dkk-3), based on the CMV promoter-driven SGE system (Ad-SGE-REIC) and compared the therapeutic utility of Ad-SGE-REIC with that of the conventional adenoviral vectors (Ad-CMV-REIC or Ad-CAG-REIC). The results demonstrated that the CMV promoter-SGE system allows for more potent gene expression, and that the Ad-SGE-REIC is superior to conventional adenoviral systems in terms of the REIC protein expression and therapeutic effects. Since the SGE cassette can be applied for the expression of various therapeutic genes using various vector systems, we believe that this novel system will become an innovative tool in the field of gene expression and gene therapy.
KW - Adenovirus
KW - Cytomegalovirus enhancer
KW - Gene expression
KW - Human telomerase reverse transcriptase enhancer
KW - Simian virus 40 enhancer
UR - http://www.scopus.com/inward/record.url?scp=84896735946&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84896735946&partnerID=8YFLogxK
U2 - 10.3892/or.2013.2958
DO - 10.3892/or.2013.2958
M3 - Article
C2 - 24398705
AN - SCOPUS:84896735946
SN - 1021-335X
VL - 31
SP - 1089
EP - 1095
JO - Oncology reports
JF - Oncology reports
IS - 3
ER -